Four (9%) had a new or recurrent malignancy discovered within 2 years of their LGI1‐AE diagnosis [31], including melanoma (n = 2), prostate adenocarcinoma (n = 1), and appendiceal mucinous carcinoma (n = 1). This evidence concerns the gene LGI1 and prostate adenocarcinoma.